Intérêts potentiels des facteurs angiogéniques placentaires comme biomarqueurs dans la pré-éclampsie pour le clinicien (notice n° 759757)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05002cam a2200481 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250123101942.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Boulanger, Henri |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Intérêts potentiels des facteurs angiogéniques placentaires comme biomarqueurs dans la pré-éclampsie pour le clinicien |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2019.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 37 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | La responsabilité des facteurs angiogéniques placentaires dans la survenue des manifestations cliniques de la pré-éclampsie a été démontrée en 2003 avec l’implication du sFlt-1, du PlGF et du VEGF, puis en 2006 avec l’implication de l’endogline soluble. L’ischémie et l’inflammation placentaire observées au cours de la pré-éclampsie modifient leurs productions et leurs évolutions au cours de la grossesse. Au premier trimestre de la grossesse, la combinaison du PlGF à certaines informations cliniques biophysiques et biologiques permet d’obtenir un test plus performant que le dépistage habituel. Son intérêt clinique reste néanmoins à démontrer. Aux deuxième et troisième trimestres de la grossesse, le rapport sFlt-1/PlGF peut être utilisé, en présence ou en l’absence de néphropathie préexistante, pour la prédiction à court terme, l’aide au diagnostic, le pronostic et l’évaluation de l’efficacité d’un traitement pour la pré-éclampsie. Un rapport sFlt-1/PlGF < 38 et ≤ 33 exclut respectivement la survenue à court terme et le diagnostic de la pré-éclampsie. Un rapport sFlt-1/PlGF≥85, entre 20 et 34 SA, et ≥ 110, au-delà de 34 SA confirme, à l’inverse, le diagnostic de pré-éclampsie. Un rapport sFlt-1/PlGF ≥ 85 et < 85 identifie respectivement les pré-éclampsies « angiogéniques », et « non angiogéniques », dont le risque de complications maternelles et fœtales à deux semaines diffère. Un rapport sFlt-1/PlGF > 655 et > 201 conditionne également le devenir respectif à court terme des pré-éclampsies précoces et tardives. Ces valeurs pourraient, à l’avenir, être intégrées dans les recommandations afin de mieux prendre en charge cliniquement la pré-éclampsie. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The role of angiogenic factors in the onset of clinical manifestations of preeclampsia was demonstrated in 2003 by the implication of sFlt-1, PlGF and VEGF, and in 2006 by the implication of soluble endoglin. Placental ischemia and inflammation observed in preeclampsia alter both the production and progression of angiogenic factors during pregnancy. During the first trimester, the combination of PlGF with clinical, biophysical and biological factors results in a better test than the conventional one. However, the clinical value of this method remains to be confirmed. During the second and third trimesters, the sFlt-1/PlGF ratio may be used, with or without pre-existing renal disease, for short-term prediction, diagnosis, and prognosis, and to evaluate the effectiveness of preeclampsia treatment. While a sFlt-1/PlGF ratio < 38 and ≤ 33, respectively, rules out the short-term onset and diagnosis of preeclampsia, a sFlt-1/PlGF ratio ≥ 85 between 20 and 34 weeks of pregnancy and ≥ 110 beyond 34 weeks of pregnancy confirms a diagnosis of preeclampsia. Angiogenic and non-angiogenic preeclampsia are identified by a sFlt-1PlGF ≥ 85 and < 85, respectively, with the risk of maternal and fetal complications at two weeks differing between the two. Similarly, a sFlt-1/PlGF ratio > 665 and > 205, respectively, is a good short-term predictor of adverse outcomes of early and late-onset preeclampsia. These values could be incorporated into future guidelines for better clinical management of preeclampsia. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Utilisation clinique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Endogline soluble |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Pré-éclampsie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Vascular endothelial growth factor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Facteurs angiogéniques placentaires |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Soluble fms-like tyrosine kinase-1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Placental growth factor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Biomarqueurs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Soluble endoglin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Preeclampsia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Biomarkers |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Placental angiogenic factors |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Vascular endothelial growth factor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Soluble fms-like tyrosine kinase-1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Placental growth factor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clinical use |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Pre-existing renal disease |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lefèvre, Guillaume |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ahriz Saksi, Salima |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Achiche, Jedjiga |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bailleul, Sophie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ekoukou, Dieudonné |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Drouin, Dominique |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sault, Corinne |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stawiarski, Nicolas |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dupuis, Emmanuel |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Néphrologie & Thérapeutique | Volume 15 | 6 | 2019-06-26 | p. 413-429 | 1769-7255 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-nephrologie-et-therapeutique-2019-6-page-413?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-nephrologie-et-therapeutique-2019-6-page-413?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux